{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:52:59Z","timestamp":1789102379552,"version":"build-2803163510"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/mph.0000000000000500","type":"journal-article","created":{"date-parts":[[2016,1,24]],"date-time":"2016-01-24T11:24:45Z","timestamp":1453634685000},"page":"102-106","source":"Crossref","is-referenced-by-count":2,"title":["Acute Leukemia in Down Syndrome Children in Hong Kong"],"prefix":"10.1097","volume":"38","author":[{"given":"Grace Kee See","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Wing Kwan","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shau Yin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Wing","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chak Ho","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu Cheung","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Kwok Shing","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Kong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210209","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/(SICI)1096-8628(19980203)75:4<386::AID-AJMG7>3.0.CO;2-O","article-title":". Racial variation in incidence of trisomy 21: survey of 57,742 Chinese deliveries.","volume":"75","author":"Lau","year":"1998","journal-title":"Am J Med Genet"},{"key":"R2-3-20210209","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2353\/jmoldx.2009.080132","article-title":"Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 William Beaumont hospital symposium on molecular pathology.","volume":"11","author":"Xavier","year":"2009","journal-title":"J Mol Diagn"},{"key":"R3-3-20210209","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1634\/theoncologist.2008-0217","article-title":"Malignancy in children with trisomy 21.","volume":"14","author":"Rabin","year":"2009","journal-title":"Oncologist"},{"key":"R4-3-20210209","first-page":"258","article-title":". A small cohort review of neonatal transient myeloproliferative disease in Chinese children.","volume":"16","author":"Xiong","year":"2011","journal-title":"HK J Paediatr"},{"key":"R6-3-20210209","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2009-07-235291","article-title":". Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Childrens Oncology Group.","volume":"116","author":"Maloney","year":"2010","journal-title":"Blood"},{"key":"R7-3-20210209","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-10-3446","article-title":". Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Childrens Cancer Group study.","volume":"106","author":"Whitlock","year":"2005","journal-title":"Blood"},{"key":"R8-3-20210209","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1002\/cncr.27484","article-title":". Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Childrens Oncology Group trial A2971: a report from the Childrens Oncology Group.","volume":"118","author":"Sorrell","year":"2012","journal-title":"Cancer"},{"key":"R9-3-20210209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.698","article-title":". Hong Kong Paediatric Hematology Oncology Study Group. Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study.","volume":"21","author":"Li","year":"2003","journal-title":"Hematol Oncol"},{"key":"R10-3-20210209","first-page":"394","article-title":". Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL 97 study.","volume":"12","author":"Li","year":"2006","journal-title":"Hong Kong Med J"},{"key":"R11-3-20210209","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":". Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.","volume":"32","author":"Stary","year":"2014","journal-title":"J Clin Oncol"},{"key":"R12-3-20210209","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":". Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"key":"R13-3-20210209","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood.V99.3.825","article-title":". Double-delayed intensification improves event free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Childrens Cancer Group.","volume":"99","author":"Lange","year":"2002","journal-title":"Blood"},{"key":"R14-3-20210209","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2402765","article-title":". A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.","volume":"17","author":"Hasle","year":"2003","journal-title":"Leukemia"},{"key":"R15-3-20210209","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":". Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"R16-3-20210209","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2014-03-560847","article-title":". Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.","volume":"124","author":"OConnor","year":"2014","journal-title":"Blood"},{"key":"R17-3-20210209","first-page":"44","article-title":". Acute myeloid leukemia: treatment and outcome.","volume":"1","author":"Li","year":"1996","journal-title":"HK J Paediatr (New Series)"},{"key":"R18-3-20210209","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/08880018.2010.533249","article-title":". Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children.","volume":"28","author":"Zhai","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"key":"R19-3-20210209","first-page":"123","article-title":". 2011 Annual Scientific Meeting: Hong Kong Paediatric Hematology and Oncology Study Group. Outcome of NOPHO-AML 2004 Study for Children with Acute Myeloid Leukemia (AML).","volume":"17","author":"Ha","year":"2012","journal-title":"HK J Paediatr (New Series)"},{"key":"R20-3-20210209","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2005.05906.x","article-title":". Treatment for myeloid leukemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.","volume":"132","author":"Rao","year":"2005","journal-title":"Br J Haematol"},{"key":"R21-3-20210209","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3324\/haematol.2013.089425","article-title":". Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.","volume":"99","author":"Blink","year":"2014","journal-title":"Haematologica"},{"key":"R22-3-20210209","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00277-005-0045-5","article-title":". Optimal treatment intensity in children with Down syndrome and myeloid leukemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.","volume":"85","author":"Abildgaard","year":"2006","journal-title":"Ann Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000000500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:48:00Z","timestamp":1620964080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201603000-00003"}},"subtitle":["Retrospective Review"],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000500","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}